Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

383 Press Releases
DateTitleCompany
21 Sep 16 New survey reveals 9 out of 10 patients with IPF were happy with the way their doctor told them about their IPF diagnosis Boehringer Ingelheim,
Published by
Ogilvy Healthworld
09 Sep 16 Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Aug 16 ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa® (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Aug 16 Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Jul 16 First Study Initiated to Evaluate the Effect of Ofev® Treatment on Biomarkers that may Predict IPF Progression Boehringer Ingelheim ,
Published by
PharmiWeb.com
27 Jul 16 First Study Initiated to Evaluate the Effect of Ofev® Treatment on Biomarkers that may Predict IPF Progression Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
22 Jul 16 Worldwide Clinical Trials Survey Reveals How Sponsors View the Role of CROs in Clinical Development Boehringer Ingelheim,
Published by
PharmiWeb.com
20 Jul 16 The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe Boehringer Ingelheim,
Published by
PharmiWeb.com
15 Jul 16 Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines Boehringer Ingelheim ,
Published by
PharmiWeb.com
30 Jun 16 INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients Boehringer Ingelheim,
Published by
Business Wire
27 Jun 16 New analysis of INPULSIS® trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria Boehringer Ingelheim,
Published by
Business Wire
27 Jun 16 Sanofi and Boehringer Ingelheim Have Reached Definitive Agreements to Swap Sanofi’s Animal Health and Boehringer Ingelheim’s Consumer Healthcare Businesses Boehringer Ingelheim,
Published by
Business Wire
12 Jun 16 New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes Boehringer Ingelheim GmbH,
Published by
Business Wire
02 Jun 16 Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib Boehringer Ingelheim,
Published by
PR Newswire
23 May 16 Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing Boehringer Ingelheim,
Published by
Business Wire
18 May 16 Phase III VivaTinA-asthma® study results show that tiotropium improves lung function in children who continue to experience symptoms despite taking other maintenance therapies Boehringer Ingelheim,
Published by
PharmiWeb.com
16 May 16 New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with IPF Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
09 May 16 The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer Boehringer Ingelheim (Canada) Ltd.,
Published by
PR Newswire
29 Mar 16 FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD Health-Related Quality of Life Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
11 Apr 16 Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy Boehringer Ingelheim ,
Published by
PharmiWeb.com
13 Apr 16 Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
04 Apr 16 Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations Boehringer Ingelheim,
Published by
Business Wire
15 Mar 16 Boehringer Ingelheim Cares Foundation and AmeriCares Launch Health Coach Program for the Uninsured Boehringer Ingelheim Cares Foundation,
Published by
PR Newswire
06 Apr 16 Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations Boehringer Ingelheim ,
Published by
PharmiWeb.com
19 Apr 16 Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology Boehringer Ingelheim ,
Published by
PharmiWeb.com
23 Mar 16 Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate) Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
27 Apr 16 VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration VTU Technology and Boehringer Ingelheim,
Published by
VTU Technology
13 Apr 16 Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology Boehringer Ingelheim,
Published by
Business Wire
01 Apr 16 FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray for COPD Health-Related Quality of Life Boehringer Ingelheim ,
Published by
PharmiWeb.com
10 Mar 16 New Analyses: Adding SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Effective for Uncontrolled Asthma – Regardless of Allergy Subtype Boehringer Ingelheim,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.